• Mannitol increased ATO concentration in CSF.
Introduction
Approximately three to five percent of acute promyelocytic leukemia (APL) patients will have an extramedullary relapse in their lifetimes, most commonly in the central nervous system (CNS). 1 The most appropriate approach for clinical management of CNS relapse in APL patients remains controversial. Several case reports have suggested intrathecal chemotherapy with allogenic or autologous hematopoietic stem cell transplantation (HSCT) as a promising therapeutic strategy; [2] [3] [4] [5] however, the existence of unfavorable outcomes has limited the applicability of this approach.
The major obstacle to all treatments for CNS APL is the need for the therapeutic drugs to penetrate the blood brain barrier (BBB). Although ATO and all-trans retinoic acid (ATRA) are among the frontline medications for APL intra-marrow treatment, 6-10 these water soluble medicines have limited ability For personal use only. on October 31, 2017. by guest www.bloodjournal.org From to cross the BBB and cannot reach therapeutically effective levels in CSF. 11, 12 When taking regular oral dosages, the ATO level in CSF has been reported to reach only 17.7% of the corresponding levels in plasma. 11 Previously, we had carried out investigations of the potential efficacy of combining a mannitol intravenous infusion with the ATO therapy using a rabbit model, and we showed that the approach caused a transient increase in the BBB permeability for ATO, thereby increasing the ATO concentration in CSF to therapeutic levels. 13 Our in vitro experiments using human cortical neurons revealed a differential tolerance of APL blasts and to different concentrations of ATO. 14, 15 In subsequent studies we also identified a safe range of ATO concentrations in human CNS. [16] [17] [18] The results from these collective studies allowed for an ATO concentration to be achieved in CSF that was both safe and therapeutic. 19 Here, we describe our efforts to extend the application of our method to additional patients and we discuss the efficacy of this treatment regimen and the favorable prognosis that was observed during long-term follow-up.
Patients and methods
The study protocol was reviewed and approved by the University Medical Ethics Committee, and signed informed consent was obtained from all patients or their legal guardians. The study was conducted in accordance with the Declaration of Helsinki. Clinical records from the Hematology Department of the First Affiliated Hospital to Harbin Medical University, between 2000 and For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 2010, were reviewed for this study. In total, 17 APL patients with CNS relapse were included in this study, and were represented by 10 males and 7 females who were between 6 and 50 years old (median age: 41 years old). All patients had been diagnosed with CNS relapse based on clinical symptoms and confirmed by morphological and cytogenetic/molecular findings. Expression of the PML/RARα gene (or t(15;17)(q22;q21) transcripts) were detected in all patients CSF by reverse transcription-polymerase chain reaction (RT-PCR) assay. Clinical data of the patients are summarized in Table 1 .
Remission induction therapy
For all patients, the induction treatment was started immediately upon diagnosis of the CNS relapse. The daily protocol was as follows: a bolus infusion of 125 ml 20% mannitol mixed in 100 ml normal saline (NS) (for children ≤ 15 years: 50 ml mannitol and 50 ml NS) administered intravenously via the antecubital vein at a flow rate of 12 ~ 20 ml/min (about 8-11 minutes total); a slow intravenous infusion of 125 ml 20% mannitol plus 7.0 mg/m 2 /day ATO (for children ≤ 15 years: 50 ml mannitol and 0.16 mg/kg/day ATO) in 500 ml NS at a flow rate of 1.0 ml/min (about 9-10.5 hours total). Patients were instructed to rest in bed during the entire infusion procedure. Urine flow was measured to ensure maintenance of a rate of at least 30-50 ml/hour. Daily infusions were continued until the patient's CSF was found to be free of APL blasts/promyelocytes. In addition to routine lab tests, the level of element arsenic metabolites was measured every other day in each patient's CSF and blood samples which had been taken immediately after each day's infusion. Inductively coupled plasma mass spectroscopy (ICP-MS; Agilent Technologies, Santa Clara, CA, USA) and high performance liquid chromatography (HPLC; AMTK, Tianjin, China) were used for the measurement of arsenic levels.
Consolidation and maintenance therapy
Consolidation therapy started two weeks after the induction therapy and was repeated at two-week intervals. A total of three cycles of consolidation therapy was given to all the patients who achieved normal CSF morphology with induction treatment. For each cycle of consolidation, daily ATO and mannitol infusion (administered as described previously for the induction treatment) continued for 14 consecutive days. At the end of consolidation treatment, promyelocytic leukemia-PML/RARα fusion transcripts in CSF and BM were tested.
Absence of PML/RARα transcripts in CSF and BM (defined as complete molecular remission (CMR)) was achieved prior to commencement of lifetime maintenance therapy ( Figure 1 ). The first year after CMR, a 14-day cycle administration of ATO and mannitol was repeated at one-month intervals. In the second year, a protocol identical to that of year one was instituted, but using a three-month interval regimen. From the third year on, the protocol was administered at six-month intervals and maintained for life. PML/RARα levels were monitored at six-month intervals. If a relapse was identified, another cycle of remission induction was started. Clinical monitoring and supportive treatment followed our departmental guidlines. 6 Arsenic concentrations in urine, as well as functional markers of the cardiac system and gastrointestinal system were evaluated before and after each cycle of treatment. Arsenic levels were tested by hydride generation atomic fluorescence spectrometry (Haiguang Equipment Company, Guangzhou, China). 
Statistical analysis

Results
Patient response to induction treatment
In 16 of the 17 patients examined, abnormal blasts/promyelocytes from CSF were eliminated in 18 to 32 days (median 24 days) after start of induction treatment. Only one patient ( Table 1 , patient no. 3) was non-responsive to induction treatment after 49 days and later received ATRA and ATO alternative therapy.
All the patients tolerated the induction treatment well. There were no complaints of side effects (e.g. headache, blurred vision, pulmonary congestion, et cetera) associated with the use of mannitol. There were no documented cases of acute arsenic poisoning, which is indicated by the following symptoms: headache, nausea, vomiting, diarrhea, abdominal pain, hypotension, fever, hemolysis, seizures, and mental status changes. No patients discontinued use of ATO during the induction, and leukocytosis was rarely seen (white blood cell (WBC) count ranged from 0.7 x 10 9 /L to 10.5 x 10 9 /L for all patients). There were some cases of mild liver enzyme changes and mild non-hematologic toxicity associated with ATO, but in all instances these abnormalities resolved with the use of hydroxyurea and administration of dexamethasone for 3-5 days.
Arsenic metabolite levels in the blood and CSF during induction
There were no significant differences in the level of arsenic metabolites between children and adults (data not shown). The dynamic changes of functional ATO metabolites in paired blood and CSF samples are shown in 
Clinical outcome and chronic toxicity
Of the 16 patients who responded to induction therapy, all (94.1%) achieved CMR after the first consolidation cycle. Nine of these patients retained their CMR status during the follow-up period (median of 92 months, range of 70 to 125 months, so that the RFS rate after first CMR was 52.9% ( Figure 3A ).
Among the other seven patients, there were one to three relapses in BM or in CNS after their first CMR. All seven of these patients responded well to ATO and mannitol during re-induction: five of them achieved CMR again and stayed free of relapse; two died after withdrawing treatment 3-5 months after their second or third remission. The only patient that did not respond to the treatment 
Discussion
At present, the most widely used method to treat APL CNS relapse is intrathecal combination chemotherapy of methotrexate (MTX), cytarabine (Arac), and hydrocortisone for induction therapy, with consolidation therapy using intrathecal chemotherapy plus systemic chemotherapy and followed by a mandatory HSCT. 21, 22 Intrathecal therapy requires a lumbar puncture, which is an invasive, time-consuming and painful maneuver that may induce trauma or drug misdistribution throughout the neuro-axis. 23 Systemic chemotherapy could be restricted when severe adverse effects develop, such as cardiotoxicity or neutropenia. HSCT is indicated for maintenance therapy of CNS APL, 24 but the morbidity and mortality associated with HSCT continue to limit its widespread application.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Another therapeutic option for CNS relapse is the use of the potent reagent ATO, which is also the first choice for treating a BM relapse. Experience from ours and other clinics have demonstrated that regular ATO intravenous infusion plus oral ATRA could induce complete remission in newly diagnosed APL and BM recurrence. 6, 21, 22, 25 However, combination ATRA and ATO therapy should be used cautiously because of the risk of severe side effects, including differentiation syndrome and cardiotoxicity. Therefore, in this study, we chose ATO only plus mannitol for treating extrathecal relapse. Conventional administration of ATO does not increase arsenic levels in CSF to a similar therapeutic level as found in blood, with CSF levels only reaching 17.7% of the corresponding plasma level. 11 This is because ATO is a water soluble medicine and not capable of crossing the BBB and entering the CSF. This barrier, however, could be overcome (in a reversible manner) by intravenously administering the hyperosmotic agent mannitol. 13, 18, 19 Combining mannitol with the ATO solution significantly increased arsenic migration into CSF. It has been shown that after antecubital venous injection of a 20% mannitol bolus, the BBB permeability to ATO was temporarily increased for at least 90 minutes 13 . In the present study, immediately after the bolus of mannitol, ATO was infused at a relatively slow speed followed by another simultaneous dose of 20% mannitol.
We believe this slow speed infusion strategy not only helped to maintain the BBB permeability to ATO at a consistently high level but also decreased ATO's acute toxicity. Furthermore, the elemental arsenic levels in CSF were Leukocytosis is a side effect that frequently occurs during newly diagnosed APL induction treatment, 6 but it was not seen in the CNS relapse cases of the current study. Although the ATO dosages were the same (7 mg/m 2 /day for adults, 0.16 mg/kg/day for children ≤ 15 years), the peripheral WBC count only remained low (ranging from 0.7 x 10 9 /L to 10.5 x 10 9 /L), and there were no reports of discontinuation or reduction of ATO due to this parameter.
Differentiation syndrome-like respiratory distress did not develop in any patient.
Other reported adverse effects, including asymptomatic QT prolongation, skin rash, facial edema, peripheral neuropathy, musculoskeletal pain, and dryness of mouth, were not reported as experienced by the patients in this study.
Regarding mannitol, the dispensed dosage was 20-50 g/day dissolved in NS, and the urine output was greater than 30-50 ml/hour. Therefore, possible adverse effects of mannitol were efficiently prevented.
Another important feature of ATO therapy in this study was the practice of a life-long post-remission therapy. Unlike some European groups who used For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 2-year post-remission treatment and American groups who used 1-year postremission treatment, 26, 27 we found that maintenance therapy for the remainder of life benefited the CNS APL patients by decreasing relapse rates over the long-term. In a previous study from our group, the relapse rate was found to be highly correlated with post-remission therapy. 6 In the current study, The key advantages of this non-invasive method were that it seldom caused drug resistance and that the cost and toxicity of ATO was much lower than chemotherapy and myeloablative or nonmyeloablative HSCT.
In conclusion, the present study provided a novel protocol for the use of single-agent ATO preceded and accompanied by mannitol for APL relapse in CNS patients. Our results demonstrated that its therapeutic efficacy was comparable with that of newly diagnosed APL treated with ATO and that this cost-effective strategy seldom caused drug resistance. Furthermore, this approach was non-invasive, with minimal toxicity, and without significant risk for the development of second malignancy. Taken together, this regimen should be considered as a new therapeutic option for CNS APL. 
